Comparative Pharmacology
Head-to-head clinical analysis: VASERETIC versus ZESTRIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VASERETIC versus ZESTRIL.
VASERETIC vs ZESTRIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vaseretic is a combination of enalapril maleate (an angiotensin-converting enzyme inhibitor) and hydrochlorothiazide (a thiazide diuretic). Enalapril inhibits ACE, reducing angiotensin II formation, decreasing aldosterone secretion, and lowering blood pressure. Hydrochlorothiazide increases sodium and chloride excretion by inhibiting the Na+-Cl- symporter in the distal convoluted tubule, leading to diuresis and vasodilation.
Lisinopril competes with angiotensin I for binding to angiotensin-converting enzyme (ACE), inhibiting its activity, thereby preventing conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This leads to decreased blood pressure, reduced aldosterone secretion, and decreased sodium and water retention.
One tablet (10 mg enalapril maleate/25 mg hydrochlorothiazide) orally once daily; may increase to 2 tablets daily if needed.
10 mg orally once daily initially; titrate to 20-40 mg orally once daily. Maximum 80 mg/day.
None Documented
None Documented
Enalaprilat: 35–38 hours (terminal). Clinically, effective half-life ~11 hours. Prolonged in renal impairment (CrCl <30 mL/min: up to 60 hours).
Terminal elimination half-life is about 12 hours for lisinopril; in heart failure, half-life may be prolonged. Steady-state achieved in 2-3 days.
Renal: 60% (enalaprilat); biliary/fecal: 33% (enalaprilat). Unchanged enalapril: <5% in urine.
Primarily renal (approximately 70% unchanged), with the remainder excreted as inactive metabolites via feces and urine.
Category C
Category C
ACE Inhibitor/Diuretic Combination
ACE Inhibitor